769 related articles for article (PubMed ID: 30142876)
1. Radiation Sensitization of Basal Cell and Head and Neck Squamous Cell Carcinoma by the Hedgehog Pathway Inhibitor Vismodegib.
Hehlgans S; Booms P; Güllülü Ö; Sader R; Rödel C; Balermpas P; Rödel F; Ghanaati S
Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30142876
[TBL] [Abstract][Full Text] [Related]
2. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma.
Erdem GU; Sendur MA; Ozdemir NY; Yazıcı O; Zengin N
Curr Med Res Opin; 2015 Apr; 31(4):743-56. PubMed ID: 25690490
[TBL] [Abstract][Full Text] [Related]
3. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
Proctor AE; Thompson LA; O'Bryant CL
Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
[TBL] [Abstract][Full Text] [Related]
4. Taselisib (GDC-0032), a Potent β-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PIK3CA Alterations.
Zumsteg ZS; Morse N; Krigsfeld G; Gupta G; Higginson DS; Lee NY; Morris L; Ganly I; Shiao SL; Powell SN; Chung CH; Scaltriti M; Baselga J
Clin Cancer Res; 2016 Apr; 22(8):2009-19. PubMed ID: 26589432
[TBL] [Abstract][Full Text] [Related]
5. Anticancer drugs and the regulation of Hedgehog genes GLI1 and PTCH1, a comparative study in nonmelanoma skin cancer cell lines.
Olesen UH; Bojesen S; Gehl J; Haedersdal M
Anticancer Drugs; 2017 Nov; 28(10):1106-1117. PubMed ID: 28799948
[TBL] [Abstract][Full Text] [Related]
6. Reduced proliferation and colony formation of head and neck squamous cell carcinoma (HNSCC) after dual targeting of EGFR and hedgehog pathways.
Liebig H; Günther G; Kolb M; Mozet C; Boehm A; Dietz A; Wichmann G
Cancer Chemother Pharmacol; 2017 Feb; 79(2):411-420. PubMed ID: 28110457
[TBL] [Abstract][Full Text] [Related]
7. Hedgehog pathway inhibitor in combination with radiation therapy for basal cell carcinomas of the head and neck : First clinical experience with vismodegib for locally advanced disease.
Schulze B; Meissner M; Ghanaati S; Burck I; Rödel C; Balermpas P
Strahlenther Onkol; 2016 Jan; 192(1):25-31. PubMed ID: 26449347
[TBL] [Abstract][Full Text] [Related]
8. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
Cirrone F; Harris CS
Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
[TBL] [Abstract][Full Text] [Related]
9. Vismodegib: a guide to its use in locally advanced or metastatic basal cell carcinoma.
Lyseng-Williamson KA; Keating GM
Am J Clin Dermatol; 2013 Feb; 14(1):61-4. PubMed ID: 23329081
[TBL] [Abstract][Full Text] [Related]
10. Discovery and preclinical development of vismodegib.
Gould SE; Low JA; Marsters JC; Robarge K; Rubin LL; de Sauvage FJ; Sutherlin DP; Wong H; Yauch RL
Expert Opin Drug Discov; 2014 Aug; 9(8):969-84. PubMed ID: 24857041
[TBL] [Abstract][Full Text] [Related]
11. Laser-assisted topical delivery of vismodegib reduces hedgehog gene expression in human basal cell carcinomas in vivo.
Olesen UH; Pedersen KK; Togsverd-Bo K; Biskup E; Nielsen AL; Jackerott M; Clergeaud G; Andresen TL; Haedersdal M
Lasers Surg Med; 2024 Mar; 56(3):239-248. PubMed ID: 38311811
[TBL] [Abstract][Full Text] [Related]
12. Ablative fractional laser treatment reduces hedgehog pathway gene expression in murine basal cell carcinomas.
Pedersen KK; Granborg JR; Lerche CM; Litman T; Olesen UH; Hædersdal M
Lasers Med Sci; 2024 Feb; 39(1):55. PubMed ID: 38308119
[TBL] [Abstract][Full Text] [Related]
13. Vismodegib: in locally advanced or metastatic basal cell carcinoma.
Keating GM
Drugs; 2012 Jul; 72(11):1535-41. PubMed ID: 22788238
[TBL] [Abstract][Full Text] [Related]
14. Genetic landscape and ligand-dependent activation of sonic hedgehog-Gli1 signaling in chordomas: a novel therapeutic target.
Yang C; Yong L; Liang C; Li Y; Ma Y; Wei F; Jiang L; Zhou H; He G; Pan X; Hai B; Wu J; Xu Y; Liu Z; Liu X
Oncogene; 2020 Jun; 39(24):4711-4727. PubMed ID: 32404987
[TBL] [Abstract][Full Text] [Related]
15. Role of apoptosis in basal cell and squamous cell carcinoma formation.
Erb P; Ji J; Wernli M; Kump E; Glaser A; Büchner SA
Immunol Lett; 2005 Aug; 100(1):68-72. PubMed ID: 16054233
[TBL] [Abstract][Full Text] [Related]
16. Vismodegib.
Meiss F; Andrlová H; Zeiser R
Recent Results Cancer Res; 2018; 211():125-139. PubMed ID: 30069764
[TBL] [Abstract][Full Text] [Related]
17. Ultraviolet damage, DNA repair and vitamin D in nonmelanoma skin cancer and in malignant melanoma: an update.
Reichrath J; Rass K
Adv Exp Med Biol; 2014; 810():208-33. PubMed ID: 25207368
[TBL] [Abstract][Full Text] [Related]
18. Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib.
Saintes C; Saint-Jean M; Brocard A; Peuvrel L; Renaut JJ; Khammari A; Quéreux G; Dréno B
J Eur Acad Dermatol Venereol; 2015 May; 29(5):1006-9. PubMed ID: 24980899
[TBL] [Abstract][Full Text] [Related]
19. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
20. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449).
Meani RE; Lim SW; Chang AL; Kelly JW
Australas J Dermatol; 2014 Aug; 55(3):218-21. PubMed ID: 25117162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]